Literature DB >> 10467976

Guanfacine and secondary mania in children.

J P Horrigan1, L J Barnhill.   

Abstract

INTRODUCTION: Guanfacine hydrochloride is an alpha-2 adrenergic agonist, which has gained recent attention in the field of child and adolescent psychiatry. This medication has been described as effective in the management of attention-deficit hyperactivity and tic disorders, with minimal side effects.
METHODS: Presented here are five cases of behavioral activation in children treated with guanfacine.
RESULTS: In each instance the clinical presentation resembled an acute hypomanic or manic episode. The dose of guanfacine was 0.5 mg/day. Later investigation revealed that all of the youngsters had clear risk factors (clinical and/or familial) for bipolar disorder.
CONCLUSIONS: It appears as though guanfacine may be capable of precipitating secondary mania in vulnerable children.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467976     DOI: 10.1016/s0165-0327(98)00183-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

1.  Tourette's Disorder.

Authors:  Gholson J Lyon; David Shprecher; Barbara Coffey; Roger Kurlan
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

Review 2.  Bipolar disorder in youth.

Authors:  G A Carlson; S E Meyer
Journal:  Curr Psychiatry Rep       Date:  2000-04       Impact factor: 5.285

Review 3.  Mania in neurologic disorders.

Authors:  M F Mendez
Journal:  Curr Psychiatry Rep       Date:  2000-10       Impact factor: 5.285

Review 4.  Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.

Authors:  Lawrence Scahill
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 5.  Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Authors:  Robert L Findling; Shawn A Candler; Azmi F Nasser; Stefan Schwabe; Chungping Yu; Jennie Garcia-Olivares; Welton O'Neal; Jeffrey H Newcorn
Journal:  CNS Drugs       Date:  2021-05-18       Impact factor: 5.749

6.  European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment.

Authors:  Veit Roessner; Kerstin J Plessen; Aribert Rothenberger; Andrea G Ludolph; Renata Rizzo; Liselotte Skov; Gerd Strand; Jeremy S Stern; Cristiano Termine; Pieter J Hoekstra
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785

Review 7.  Lifetime evolution of ADHD treatment.

Authors:  Federico Mucci; Barbara Carpita; Giovanni Pagni; Alessandra Della Vecchia; Sarah Bjedov; Andrea Pozza; Donatella Marazziti
Journal:  J Neural Transm (Vienna)       Date:  2021-05-15       Impact factor: 3.850

8.  Adolescent with tourette syndrome and bipolar disorder: a case report.

Authors:  Se-Hoon Shim; Young-Joon Kwon
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

Review 9.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.

Authors:  Veit Roessner; Heike Eichele; Jeremy S Stern; Liselotte Skov; Renata Rizzo; Nanette Mol Debes; Péter Nagy; Andrea E Cavanna; Cristiano Termine; Christos Ganos; Alexander Münchau; Natalia Szejko; Danielle Cath; Kirsten R Müller-Vahl; Cara Verdellen; Andreas Hartmann; Aribert Rothenberger; Pieter J Hoekstra; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-11-10       Impact factor: 4.785

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.